FRANKFURT (Reuters) - Actavis, the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than 2 billion euros ($2.6 billion) this year, driven by patent expiries in Europe and strong demand in the United States.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment